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To advance our understanding and treatment of disease, research immunologists have
been called-upon to place more centralized emphasis on impactful human studies. Such
endeavors will inevitably require large-scale study execution and data management regu-
lation (“Big Biology”), necessitating standardized and reliable metrics of immune status
and function. A well-known example setting this large-scale effort in-motion is identify-
ing correlations between eventual disease outcome and T lymphocyte phenotype in large
HIV-patient cohorts using multiparameter flow cytometry. However, infection, immunodefi-
ciency, and autoimmunity are also characterized by correlative and functional contributions
of B lymphocytes, which to-date have received much less attention in the human Big
Biology enterprise. Here, we review progress in human B cell phenotyping, analysis, and
bioinformatics tools that constitute valuable resources for the B cell research community
to effectively join in this effort.
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INTRODUCTION
Like other areas of immunology, much of our understanding of B
cell biology is based on laboratory mouse studies. Despite boun-
tiful experimental capabilities, mouse systems are sub-optimal
models of normal human B cell function or of genuine human
disease, as demonstrated by failed interspecies transfer of thera-
peutic protocols in clinical trials (Davis, 2008). However, findings
in mice can motivate informative investigation in humans, pro-
vided that we acknowledge key differences: (1) humans are largely
outbred, (2) they live in diverse environments that researchers
have no control over and have limited abilities to monitor, and
(3) most human tissues are inaccessible, and accessible lymphoid
tissues may not necessarily drain the area of interest. For these
latter reasons, peripheral blood mononuclear cell (PBMC) prepa-
rations are the most commonly analyzed cell source in human
immunology research. With the exception of blatant systemic sep-
sis, PBMC should be viewed as a sentinel population that indirectly
informs us of immunological activity occurring elsewhere. Similar
to observing diversely dressed people on a daily commute, we can
only infer the origins, occupations, accomplishments, and capa-
bilities of PBMC based on previous correlative evidence. Such cor-
relations are only meaningfully applied to generalized conclusions
about humans if we have large numbers of subjects and a resource
base (labor, materials, instrumentation, and data management
infrastructure) enabling utilization of human samples to their
fullest extent.
Besides our devoted curiosity, an important rationale for invest-
ing in human B cell research is based on the observation that B
cell-depletion can result in clinical improvement in autoimmune
diseases, including systemic lupus erythematosus (SLE), rheuma-
toid arthritis, primary Sjögren’s Syndrome, type 1 diabetes, and
neurological disorders, such as multiple sclerosis (Anolik et al.,
2004, 2007; Leandro et al., 2006; Pranzatelli et al., 2006; Steinfeld
et al., 2006; Dass et al., 2008; Hauser et al., 2008; Jacob et al., 2008;
Roll et al., 2008; Moller et al., 2009; Nakou et al., 2009; Pescovitz
et al., 2009; Meijer et al., 2010; Iwata et al., 2011a). Importantly,
only some, but not all effects attributed to B cells are autoantibody-
mediated (Anolik et al., 2004; Sanz, 2011), an outcome also
observed in mouse models (Chan and Shlomchik, 1998). How-
ever, it is not entirely clear exactly which antibody-independent
B cell functions (antigen presentation, cytokine production, or
lymphoid structure development; Lund and Randall, 2010; Mar-
cus et al., 2011), when absent, account for the therapeutic benefit.
Understanding which B cell subsets are responsible for which func-
tions in these diseases, in addition to identifying how a “signature”
profile of an individual subject’s collection of subsets may correlate
with disease outcome could eventually allow greater optimization
of targeted therapies (Anolik et al., 2009; Sanz and Lee, 2010).
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B CELL SUBSETS IN HEALTHY HUMANS
Newly formed transitional B cells with an intact B cell receptor
(BCR) emigrate from bone marrow into peripheral circulation and
secondary lymphoid organs (Anolik et al., 2009). After cessation
of B cell-depletion therapy, the earliest transitional B cells recon-
stituting the human periphery are CD10+CD38highCD24high, and
due to an inactive mitochondrial transporter protein, can also
retain reagent dyes such as Mitotracker Green® (MTG; Wirths
and Lanzavecchia, 2005; Blair et al., 2010). Transitional B cells
are further subdivided into “T1” and “T2”, as well as CD10neg
MTG-retaining “T3” cells, based on incrementally lower expres-
sion of CD24 and CD38, inversely correlating with time of
reconstitution (Palanichamy et al., 2009). In vitro, these cells are
capable of stepwise differentiation into mature-naïve-phenotype
B cells, although their obligate precursor-progeny relationships
in vivo await confirmation. Similar to T3, mature-naïve B cells
are CD10negCD38low/neg, but extrude MTG (Wirths and Lanza-
vecchia, 2005). Compared with transitional-phenotype B cells, the
mature-naïve fraction survives longer in culture, and divides more
readily upon BCR engagement by cognate antigen (Wirths and
Lanzavecchia, 2005).
B cell receptor engagement and B cell costimulation through
cell-surface CD19 and CD21 on mature-naïve B cells can stim-
ulate activation and differentiation (Harwood and Batista, 2010;
Kurosaki, 2011), which ideally contribute to eliminating invading
organisms. Early cell-surface changes associated with B cell activa-
tion include the up-regulation of CD40, CD80, CD86, and CD69.
More than half of naïve-phenotype B cells express the Fcε receptor
CD23 (Kikutani et al., 1986; Kumagai et al., 1989; Klein et al., 1998;
Tangye et al., 1998; Quach et al., 2011). Although CD23 can be up-
regulated after in vitro stimulation (Pelton et al., 1991), tonsilar B
cells showing evidence of recent activation lack CD23 expression
(Kolar et al., 2007). Whether this differential expression reflects
distinct subsets or a consequence of in vivo stimuli is unknown.
Activated B cells receiving T cell help in secondary lymphoid
tissue follicles can become germinal center (GC) B cells. GC B
cells proliferate and can class-switch the BCR constant region
from IgM/IgD to IgG, IgA, or IgE (Pascual et al., 1994). Addi-
tionally, the Ig V region genes of GC B cells can undergo somatic
hypermutation to change the affinity of the encoded BCR for its
cognate antigen, thus allowing subsequent antigen-driven selec-
tion and clonal expansion of high-affinity B cells. When peripheral
tolerance is intact, these B cells are mostly not self-reactive, and
differentiate into antibody-secreting plasma cells or into memory
B cells that can rapidly respond to a subsequent encounter with an
invading organism.
Human GC B cells, in vitro-activated naïve B cells, and those
with specific and rapid recall responses to previously encountered
antigens (memory) express cell-surface CD27. B cell CD27 expres-
sion correlates with greater cell size (Agematsu et al., 1997; Wirths
and Lanzavecchia, 2005), proliferative capacity (Tangye et al.,
2003a,b; Macallan et al., 2005; Good et al., 2009), antigen presenta-
tion capacity (Good et al., 2009),and differentiation into antibody-
secreting cells (ASC; Tangye et al., 2003b). Because ASC in circu-
lation are at low frequencies, because few circulating CD27+ B
cells show evidence of on-going proliferation, and because GC are
generally confined to lymphoid tissues, most CD27+ B cells in the
peripheral pool of healthy humans are typically considered “mem-
ory B cells.” Consistent with this designation, the Ig V regions of
CD27+ B cells tend to have somatic hypermutations with DNA
sequence characteristics of antigen selection, regardless of whether
the cells are IgDneg [mostly class-switched memory (“switched
memory”)] or are IgD/IgM+ (“non-switched memory”; Pascual
et al., 1994; Dunn-Walters et al., 1995; Klein et al., 1998; Tiller
et al., 2007). Reports differ on whether the non-switched memory
and switched memory compartments share an Ig Vh repertoire
(Odendahl et al., 2000; Weller et al., 2008; Seifert and Kuppers,
2009; Wu et al., 2010), making it uncertain whether or not the lat-
ter compartment derives from the former. Deep sequencing and
clonality analysis showed that non-switched memory cells have a
lower frequency of SHM than switched memory, and failed to find
evidence that non-switched memory cells were clonally related
to the switched memory pool (Wu et al., 2011). Although func-
tional mouse studies show that at least some of the IgM memory
pool maintains long-term IgG memory against protein antigen
(Dogan et al., 2009; Pape et al., 2011), the human non-switched
memory pool has characteristics not shared with the switched
memory fraction. These characteristics include GC-independent
somatic hypermutation (Weller et al., 2001), attributes of puta-
tive B1 B cells, regulatory B cells, and splenic marginal zone-like
B cells that contribute carbohydrate-reactive antibody responses
to encapsulated bacteria (Kruetzmann et al., 2003; Tsuiji et al.,
2006; Wasserstrom et al., 2008; Griffin et al., 2011; Iwata et al.,
2011b). Thus, the IgD+CD27+ pool is likely a composite of at least
two, if not several functional subsets, possibly together with some
precursors that will class-switch to feed the switched memory pool.
Some class-switched human B cells are IgDnegCD27neg
(“double-negative”) that are typically less than 5% of the CD19+
population in healthy subjects (Fecteau et al., 2006; Wei et al.,
2007). mRNA analysis indicates that a minor population of this
fraction expresses IgM without IgD (Wu et al., 2011). Both CD27+
(switched memory) and CD27neg (double-negative) IgDneg frac-
tions can be stimulated to secrete immunoglobulin against tetanus
toxin and influenza virus (Wirths and Lanzavecchia, 2005), sug-
gesting involvement in prior vaccine responses. Apart from CD27,
These two B cell fractions have similar surface phenotypes and
have somatically mutated Ig V regions (Wirths and Lanzavecchia,
2005; Fecteau et al., 2006; Wei et al., 2007). However, fewer double-
negative B cells have somatic mutations than switched memory B
cells (Fecteau et al., 2006; Wei et al., 2007), suggesting that the
former fraction is a mixture of both true memory B cells and
something else, possibly transient effectors. Deep sequencing and
clonality analysis suggest that double-negative B cells can become
switched memory and vice-versa (Wu et al., 2011). Thus, the pools
of memory B cells in circulation may go through distinct differ-
entiation stages in which CD27 expression reversibly changes in
class-switched B cells.
Appropriately activated B cells can differentiate into ASC, which
help resolve primary infections and are also maintained for long-
term protection (Fairfax et al., 2008; Oracki et al., 2010). Although
rare in the blood of healthy, unchallenged individuals, PB ASC
rapidly and transiently increase within 1 week after vaccination
or infection (Blink et al., 2005; Odendahl et al., 2005; Gonzalez-
Garcia et al., 2006; Wrammert et al., 2008, 2011; Blanchard-Rohner
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et al., 2009; Halliley et al., 2010; Lee et al., 2010, 2011; Qian et al.,
2010; Li et al., 2012). The associated increase in serum antibody
titer is sustained (Halliley et al., 2010), and can last for the lifetime
of the individual (Slifka et al., 1998; Amanna et al., 2007). These
sustained antibody levels are likely provided by long-lived ASC
in other tissues, such as bone marrow, where they are abundant
(Morell et al., 1970; McMillan et al., 1972; Slifka et al., 1998).
Most human blood CD19+CD27highCD38high ASC are con-
sidered plasmablasts due to evidence suggesting on-going cell
division (Odendahl et al., 2005; Wirths and Lanzavecchia, 2005;
Gonzalez-Garcia et al., 2006; Halliley et al., 2010; Qian et al., 2010).
Plasmablasts can be distinguished from plasma cells, a term ide-
ally reserved for truly terminally differentiated ASC (Fairfax et al.,
2008; Oracki et al., 2010). Plasma cell characteristics such as large
size, little to no surface immunoglobulin, and non-proliferation
correspond with expression of the adhesion molecule CD138
(syndecan-1) on CD38high B cells (Smith et al., 1996; Wirths and
Lanzavecchia, 2005; Gordon et al., 2008; Perry et al., 2008; Caraux
et al., 2010; Di Niro et al., 2010). Expression of CD138 on more
CD38high B cells compared with CD38int B cells suggests that at
least some plasmablasts may be precursors of plasma cells (Arce
et al., 2004; Fairfax et al., 2008; Oracki et al., 2010). Less than half of
blood ASC express CD138,but nearly all bone marrow ASC express
this molecule (Medina et al., 2002; Gonzalez-Garcia et al., 2006;
Fairfax et al., 2008; Oracki et al., 2010). Whereas circulating plas-
mablasts may provide the transient boost seen in existing serum
Ig levels after vaccination or acute infection, long-lived CD138+
bone marrow plasma cells are likely responsible for long-lived
antigen-reactive serum antibody, because concurrently detectable
circulating memory B cells are not required for long-lived specific
antibody in the serum (McMillan et al., 1972; Slifka et al., 1998;
Bernasconi et al., 2002; Mamani-Matsuda et al., 2008). Differential
expression of human CD38, CD138, and other markers includ-
ing HLA-DR and CD20 (Terstappen et al., 1990; Kantele et al.,
1996; Lakew et al., 1997; Medina et al., 2002; Tangye et al., 2003b;
Arce et al., 2004; Gonzalez-Garcia et al., 2006; Doria-Rose et al.,
2009; Jacobi et al., 2010b) may alternatively or additionally rep-
resent ASC subsets that derive from independent differentiation
pathways in blood, bone marrow, and possibly other tissues.
B cells that can impair or suppress immune reactions are
referred to as “regulatory” B cells (Bregs; Mauri and Bosma,
2012; Kaminski and Sanz, 2013). Antibody-independent suppres-
sive activity can be mediated by antigen presentation to promote
mouse regulatory T cell development (Redfield et al.,2011; Tadmor
et al., 2011), cytotoxicity (Jahrsdorfer et al., 2006), reducing human
T cell division (Bouaziz et al., 2010), and secreting soluble factors
that reduce expression of inflammatory cytokines by human and
mouse T cells (Blair et al., 2010; Bouaziz et al., 2010; Iwata et al.,
2011b; Ramgolam et al., 2011; Maseda et al., 2012). In vivo, mouse
B cell IL10 can limit accumulation of neutrophils and NK cells in
spleen, and bacteria-induced inflammatory foci in liver (Maseda
et al., 2012). Similarly, the most well-studied suppressive mech-
anism in human B cells is IL10 production, which can only be
detected after ex vivo stimulation (Yanaba et al., 2009; Bouaziz
et al., 2010; Iwata et al., 2011b). Such stimulation includes innate-
like (e.g., TLR) and helper T cell (CD40) signals alone or together
with cognate antigen (Duddy et al., 2007; Yanaba et al., 2009;
Bouaziz et al., 2010; Iwata et al., 2011b). IL10-competent B cells are
considered to be a distinct functional subset or collection of sub-
sets because their IL10 production occurs in a relatively polarized
fashion in which co-expression of inflammatory cytokines is disfa-
vored (Amel Kashipaz et al., 2003; Duddy et al., 2007; Yanaba et al.,
2009). IL10 can be expressed by most commonly defined human
B cell subsets, and conclusions differ about whether the “most effi-
cient” Bregs are contained within the CD24highCD38highCD27neg
(Duddy et al., 2007; Blair et al., 2010; Bouaziz et al., 2010) or
within the CD27+ B cell fractions (Blair et al., 2010; Bouaziz
et al., 2010; Iwata et al., 2011b). The observed differences could
result from methodological disparity or from biological variation
and immunological circumstances among subject groups. In the
context of B cell profiling, neither single nor combinations of cell-
surface markers has definitively functioned as a surrogate for IL10
production or general regulatory capacity.
Our knowledge about human B cell subsets described above
(summarized in Table 1) offers a wealth of possibilities for diag-
nostic profiling that could help optimize therapeutic protocols
on a per-patient basis in the future. Getting to this point, how-
ever, will require validating and compiling our research findings
with an infrastructure of data organization as well as standard-
ization of how different cell populations are designated. Efforts
to standardize leukocyte ontologies have been initiated to address
NIAID’s data-sharing initiative, which aims to encourage the re-
use and the re-analysis of data to maximize the public’s investment
in biomedical research (Diehl et al., 2011; Kong et al., 2011;
Smith and Scheuermann, 2011). Effective ontology systems can
facilitate retrieval and integration of this data (Smith and Scheuer-
mann, 2011). For example, the Human Studies Database Project
has been established to form an informatics infrastructure for
inter-institutional sharing (Sim et al., 2010). This includes the
Bioinformatics Integration Support Contract, which was used to
develop a web-based immunology database and analysis portal
(ImmPort1; Kong et al., 2011). Assigning definitive nomenclature
to B cell subsets will be an on-going challenge given that few, if any
phenotypically defined populations are homogeneous in experi-
ence, function, etc. This effort will be best informed by a thorough
understanding of B cell subset changes in the context of immune
perturbation.
B CELL ALTERATIONS IN AUTOIMMUNITY SUGGEST
POSSIBLE DISEASE SIGNATURES
Our understanding of human B cell function derives from com-
parisons between healthy individuals and those with particular
immunological diseases, and among groups of patients having
the same disease with different clinical outcomes. For example,
human SLE is clinically heterogeneous (Bertsias et al., 2010),
making treatment decisions challenging. Intriguingly, long-term
remission in B cell-depleted SLE patients correlates with prefer-
ential early reconstitution of transitional-phenotype B cells after
treatment is stopped (Anolik et al., 2007). Thus, these early B
cell subsets either confer a protective effect and/or simply flourish
(at the expense of memory-phenotype B cells) in the context of
1immport.niaid.nih.gov
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Table 1 | Surface-phenotype defined human peripheral B cell subsets.
Name Type Phenotype Markers to
sub-fractionate
Ascribed functions Biomarker potential
Transitional T1 IgD+CD27neg
CD10+CD24high
CD38highMTG+
Precursor to T2; IL10
production (?)
Early reconstitution∞ SLE
remission post-BCDT
T2 IgD+CD27neg
CD10+CD24high/+
CD38high/+MTG+
Precursor to T3; IL10
production (?)
↓ IL10 in SLE
↑ ∞ transplant tolerance
↑ in SS
T3 IgD+CD27neg
CD10negCD24+/low
CD38+/lowMTG+
Precursor to mature-naïve;
IL10 production (?)
Mature-naïve IgD+CD27neg
CD10negCD24+/low
CD38+/lowMTGneg
CD23, CD69,
CD80, CD86
Precursor to GC, memory,
and antibody-secreting cells
↑ activation in SLE
Memory Double-negative IgDnegCD27neg CD21, CD24,
CD95, CXCR3
Recall responses (and
effector functions?)
↓ in SS
↑ ∞ autoAb and nephritis in SLE
Non-switched IgD+CD27+ CD1c, CD21,
CD24
Immunoprotective self
antibody (?); circulating
MZ-like (?); regulatory (?)
↓ in SLE; inverse correlation with
autoAb
IgM-only IgM+IgDnegCD27+ CD1c, CD21,
CD24
Immunoprotective self
antibody (?); circulating
MZ-like (?); regulatory (?)
↑ in SS
Switched IgMneg
IgDnegCD27+
CD21, CD24,
CD95, CXCR3
Pathogen protection;
autoimmune pathology
↑ ∞ relapse in SLE and RA
post-BCDT
↓ ∞ poor vaccine response in
elderly
Antibody-secreting
cell
Plasmablast IgDnegCD27high
CD38highCD138neg
CD20, HLA-DR Antibody secretion ↑ in SLE
Plasma cell IgDnegCD27high
CD38highCD138+
CD20, HLA-DR Antibody secretion
Markers in bold font indicate commonly defined “core” subsets; biomarker potential for T1 and T2 are merged as well plasmablast and plasma cell because they
were not experimentally distinguished from each other.
MTG, mitotracker green; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; SS, Sjögren’s syndrome; BCDT, B cell-depletion therapy; autoAb, autoantibody
levels.
∞, “correlates or positively associates with”; ↑, increased; ↓, decreased.
low disease activity. It remains to be determined whether intrin-
sic protective functions, such IL10 production (Blair et al., 2010)
are directly responsible for this outcome in SLE. In organ trans-
plant recipients, transitional-phenotype B cell deficiency and poor
IL10 production by the remaining transitional-phenotype B cells
correlate with immunosuppressive drug dependency, and in fact,
transitional B cell frequencies can predict transplant tolerance
(Newell et al., 2010). In primary Sjögren’s syndrome, the num-
ber of circulating transitional-phenotype B cells is higher than in
controls, and modestly increases further several months after B
cell-depletion therapy (Abdulahad et al., 2011). Whether this pat-
tern corresponds with particular post-depletion clinical outcomes
remains to be determined.
Systemic lupus erythematosus-patient B cells often show a
heightened state of activation, including altered protein tyrosine
phosphorylation patterns in IgD+CD27neg (naïve-phenotype)
and in total B cells (Liossis et al., 1996; Jenks and Sanz, 2009).
SLE-patient B cells also show increased Ca+2 flux, cell size, pro-
liferative capacity, antibody production, and activation-marker
expression (Kumagai et al., 1989; Pelton et al., 1991; Liossis et al.,
1996; Chang et al., 2008). Conflicting reports show lupus disease
activity correlating with either low (Kumagai et al., 1989; Chang
et al., 2008) or high (Pelton et al., 1991; Chang et al., 2008)
CD23+ B cell frequencies. These results may reflect dissimilar B
cell characterization or reflect subgroups of SLE patients with dis-
tinct CD23 B cell profiles. Our group recently described a poorly
responsive subset of mature-naïve human B cells characterized as
IgMlowCD22highCD21lowCD19lowCD32blow, which are up to 15%
autoreactive in healthy humans (Quach et al., 2011). Interestingly,
such IgMlow cells from SLE patients have modestly lower levels
of CD19 and CD22 compared with the IgMlow compartment of
healthy subjects (Quach et al., 2011). Comprehensive investiga-
tion of B cell activation alterations, including those of this novel
subset, will provide an opportunity to more clearly understand
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the mechanisms of breaking immunological tolerance in this and
in other autoimmune diseases as well as potential phenotypic
signatures that may predict their occurrence and outcomes.
Proliferating CD38+ GC structures in SLE-patient tonsils con-
tain B cells with the self-reactive BCR idiotype, 9G4, which is
typically excluded from GC in non-autoimmune control tonsils
(Pugh-Bernard et al., 2001; Cappione et al., 2005). This peripheral
checkpoint breach in SLE may be responsible for high 9G4+ serum
autoantibody titers (Isenberg et al., 1993; van Vollenhoven et al.,
1999) as well as IgG+9G4+ cells and 9G4+CD138+ plasma cells in
SLE peripheral blood, which are otherwise rare in healthy controls
(Cappione et al., 2005). Importantly, these observations demon-
strate the 9G4 idiotype system to be a valuable device for tracking
autoreactive B cells in lupus. Analysis of Sjögren’s patients showed
proportionally increased CD38highIgD+ “GC founder” B cells in
peripheral blood (Bohnhorst et al., 2001). Definitively determin-
ing to what degree these or GC-associated cells identified by other
marker combinations in the blood can predict clinical outcomes
will be advantageous for several B cell-mediated autoimmune dis-
eases. This prediction is supported by the ablation of tonsilar GC
structures in rheumatoid arthritis patients after TNF neutraliza-
tion (Anolik et al., 2008), an effective therapy in many RA patients.
Unlike transitional-phenotype B cells, rapid reconstitution of
CD27+ B cells correlates with clinical relapse of B cell-depleted
SLE and rheumatoid arthritis patients (Leandro et al., 2006; Ano-
lik et al., 2007; Roll et al., 2008; Moller et al., 2009; Nakou et al.,
2009; Iwata et al., 2011a). Thus, CD27+ memory-phenotype B
cells either contribute to and/or in other ways reflect autoimmune
pathogenesis. This may also be true for the IgDnegCD27neg double-
negative B cell population whose variably higher frequencies in
SLE correlate with high-titer autoantibody and nephritis incidence
(Huang et al., 2002; Anolik et al., 2004; Wei et al., 2007). By con-
trast, double-negative B cells in primary Sjögren’s syndrome are
proportionally reduced when measured as a fraction of CD27neg B
cells (Abdulahad et al., 2011). Reports differ on whether PB CD27+
B cells are lower (Abdulahad et al., 2011) or higher (Hansen et al.,
2002) in primary Sjögren’s syndrome. This discrepancy may result
from differences in B cell enumeration as well as differential occur-
rence of memory-phenotype B cell diversion to the parotid glands
among different patients (Hansen et al., 2002). Analysis of a lim-
ited number of patients also suggest a possible correlation between
high CD27+ B cells and lymphoma secondary to Sjögren’s (Hansen
et al., 2002). Interestingly, blocking the activity of B cell Activation
Factor of the TNF Family (BAFF) with biologics, including the
recently FDA-approved recombinant monoclonal antibody Beli-
mumab (Jefferson and Liscinsky, 2011; Sanz, 2011), effectively
reduces numbers of transitional and mature-naïve B cells while
increasing memory-phenotype B cells early after treatment in SLE
and RA (Dall’Era et al., 2007; Tak et al., 2008; Wallace et al.,
2009; Jacobi et al., 2010a). Clearly, further examination of these
memory-phenotype compartments can yield informative metrics
of disease status and may also provide further insight into the
different roles of B cell subsets among different diseases. The util-
ity of such profiling is unlikely limited to autoimmunity, because
switched memory-phenotype B cell frequencies are reduced in
older humans (≥65-years-old) compared with young adults
(Frasca et al., 2010), statistically correlating with reduced systemic
vaccine responses in the former group (Frasca et al., 2012).
Unlike the double-negative and switched memory populations,
IgD+CD27+ non-switched memory B cells are proportionally
reduced in active SLE (Wehr et al., 2004; Korganow et al., 2010;
Rodriguez-Bayona et al., 2010), inversely correlating with autoan-
tibody titers (Rodriguez-Bayona et al., 2010). Therefore, some of
the non-switched memory/IgM memory B cells may play a protec-
tive role against pathology otherwise exacerbated by IgG memory.
This conclusion is further supported by a stronger clinical cor-
relation between serum 9G4+ IgG autoantibody compared with
9G4+ IgM (Bhat et al., 2002). Such a dichotomy of pathogenic and
protective B cells has been observed in models of cardiovascular
disease (Houtkamp et al., 2001; Sjoberg et al., 2009; Ait-Oufella
et al., 2010; Kyaw et al., 2010). Curiously, in primary Sjögren’s syn-
drome, the proportion of IgM-only memory B cells (IgDnegIgM+
among CD27+ B cells) is increased compared with healthy con-
trols (Abdulahad et al., 2011). This observation may suggest that
the IgM-only population functions or is affected in this disease
distinctly from the IgD+ non-switched memory compartment,
that IgM-expressing memory cells participate differently in SLE
compared with Sjögren’s syndrome, or both.
Protective contributions of regulatory B cells in mouse models
of autoimmunity and allergy include B cell-intrinsic IL10 produc-
tion, often corresponding with innate-like (MZ B and B1 B cell)
phenotypes (Wolf et al., 1996; Zhou and Hansson, 1999; Filla-
treau et al., 2002; Mizoguchi et al., 2002; Amu et al., 2010). B cell
IL10 production can be decreased in induced autoimmune mod-
els but expanded in genetically predisposed autoimmune mice
(Yanaba et al., 2009), and is also increased in subsets of patients
with various autoimmune diseases, including those with rheuma-
toid arthritis, Sjögren’s syndrome, blistering skin disease, multiple
sclerosis, and SLE (Amel Kashipaz et al., 2003; Iwata et al., 2011b).
By contrast, one study found poor IL10 induction and regulatory
function in human lupus when focusing on the CD24highCD38high
B cell pool (Blair et al., 2010). This discrepancy could either result
from technical differences, patient cohort differences, or even a
shift in excessive IL10 production by B cells of other phenotypes.
Importantly, identifying which cells are responsible and when will
be useful for biosignature phenotyping.
Antibody-secreting cell changes may also be informative for
such profiling. Reports differ on whether increased functional and
phenotypic ASC in SLE includes patients with mild disease (Wehr
et al., 2004; Jacobi et al., 2010b; Korganow et al., 2010; Rodriguez-
Bayona et al., 2010) or correlate with high disease activity (Oden-
dahl et al., 2000; Anolik et al., 2004). The different outcomes
could reflect biological disparities in patient groups, potentially
through distinct contributions of autoantibody versus antibody-
independent B cell functions (Huang et al., 2002; Anolik et al.,
2004). It cannot be excluded that plasmablast expansion in SLE is a
consequence, rather than a cause of systemic inflammation. Inter-
estingly, HLA-DRhigh, but not HLA-DRlow, plasmablast numbers
correlate with SLE clinical manifestations (Jacobi et al., 2010b).
Further defining subsets of ASC may contribute to eventual B cell
profiling of lupus and other immunological conditions.
The wealth of information about human B cell subsets (Table 1)
and their possible functions has been gathered in a fragmented
fashion due to past constraints in resources and technology. We
thus lack a comprehensive view of human B cell biology to ade-
quately exploit for clinical benefit. However, further defining B cell
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subsets with high-dimensional flow cytometry and the appropriate
data analysis methods could establish “signatures” or patterns of
changes in B cell populations that may correlate with different
clinical outcomes.
CYTOMETRY APPROACHES TO EVALUATE HUMAN B CELLS
Using our vast knowledge of B cell subsets to optimize disease
diagnosis, prognosis, and treatment can only be accomplished
through large cohort studies driven by state-of-the-art materi-
als, analysis tools, and data management infrastructure (Harris
et al., 2009; Maecker et al., 2012). Although many considera-
tions described below are not unique to B cell cytometry, they are
worth re-iterating due to the crucial importance of consistency
in large studies. Consistency can be approached by performing
as many steps as possible side-by-side, typically after shipping
frozen cells collected at multiple clinical sites (or at multiple time-
points), then staining, and analyzing the samples together at only
one central facility. For preparing, freezing, and thawing PBMC
[by either conventional methods or by automated systems such
as Smart Tube (Smart Tube Inc., Palo Alto, CA, USA)], having
established protocols that are adhered to and documented as
such allows backtracking problematic samples for critical deci-
sions about inclusion of the data (Kaminski et al., 2012; Maecker
et al., 2012). Importantly, awareness of which elements are most
sensitive to processing allows one to circumvent the issues through
compensatory study design. For example, surface CD62L expres-
sion is affected by Ficoll and by freezing (Maecker et al., 2012).
Thus, we make it a point to find informative alternatives to such a
marker when building our B cell cytometry panels for studies using
frozen samples. Plasmablast and plasma cell detection is another
challenge. Although functional ASC are still detectable by ELISpot
after a freeze-thaw cycle, cells with only a surface marker-defined
plasmablast phenotype have a significantly reduced recovery (Kyu
et al., 2009). It is unknown if this effect is simply due to a loss of
the respective cell-surface markers per se (in which case, the cells
will be inaccurately accounted for in other populations) and/or if
specific ASC subsets are affected differentially.
Building cytometry panels (either user-assembled or with pre-
prepared lyophilized reagent cocktails, such as Lyoplates™ from
BD Biosciences) should include critical consideration of mono-
clonal antibody clones and the appropriate conjugate fluorescent
detection dyes, as well as maintaining and monitoring consistent
reagent performance as has been elaborated elsewhere (Kamin-
ski et al., 2012; Maecker et al., 2012). Also described elsewhere
are instrument set-up considerations and the extent of controls
needed, which are familiar to many flow cytometry users (Per-
fetto et al., 2006; Maecker et al., 2010, 2012; Chattopadhyay and
Roederer, 2012), but become extremely important to maintain
consistency in large studies. These elements include single-color
instrument compensation controls, fluorescence-minus-one con-
trols that help determine the lower-limits of a positive stain when
gating, and monitoring and documenting instrument set-up and
performance on different procedure days of a study. Monitoring
instrument performance as well as staining consistency is also facil-
itated by having a designated biological sample that is aliquoted
and frozen for staining with each run (Kaminski et al., 2012).
The source of this control may either be a pool of healthy control
PBMC or of hemochromatosis-patient PBMC, known to be highly
enriched for B lymphocytes without excessive perturbances in
known constituent subsets.
Ensuring consistent output is also achieved by establishing
reagent panels in which the monoclonal antibody clones and their
corresponding fluorescent conjugate detector dyes are identical for
every iteration of the procedure. The Flow Immunophenotyping
Technical Meeting at NIH (FITMaN) resulted in a proposed set
of standards for developing such panels (Maecker et al., 2012).
To ensure that due credit is attributed to the effort of panel
development and for concise referencing, the journal Cytometry
A established a specific publication mechanism: Optimized Mul-
ticolor Immunofluorescence Panel (OMIP; Roederer and Tarnok,
2010). As of August, 2012, there are 12 published OMIPs. Two of
these panels encompass multiple hematopoietic lineages, one is
for endothelial cells, one is for NK cells, and seven are for T cell
subsetting, including antigen-binding cells and effector molecule
detection. Clearly, this compilation of panels does not reflect the
contribution of B cell subsets in human immune conditions as
described above. To address this shortcoming, our group recently
developed a 12-color panel to focus on memory-phenotype B cells
(OMIP-003), although other subsets are detectable as well (Wei
et al., 2011).
The OMIP-003 memory B cell panel (Table 2) includes IgD
(more naïve) and CD27 (more differentiated) markers to derive
four “core” or parent subsets described in previous sections
(gray ovals in Figure 1). Within the parent IgD+CD27neg naïve-
phenotype fraction, displaying CD24 versus CD38 separates the
T1/T2 transitional populations from T3/mature-naïve B cells as
described above. Distinguishing T1 from T2 can be very difficult
and is best approached by overlaying or comparative gate-drawing
of a healthy bone marrow sample stained with the same panel,
because bone marrow is highly enriched for T1 with the very high-
est levels of CD38 and CD24. T3 cannot be distinguished from
mature-naïve with this memory B cell panel. Instead, an alterna-
tive panel that includes a reporter dye such as MTG is required
(Palanichamy et al., 2009). The memory B cell panel also does
not thoroughly elaborate previously investigated characteristics
of the non-switched memory core subset, such as similarity to
splenic marginal zone cells (Weller et al., 2004) or putative human
B1 B cells, whose frequency in circulation is currently debated
(Descatoire et al., 2011; Griffin et al., 2011; Perez-Andres et al.,
2011).
Within the remaining double-negative and switched memory
core B cell subsets, CD21 loss, CD95 up-regulation, and CXCR3
up-regulation can be used to assess activation and propensity to
home to inflamed tissue (Jacobi et al., 2008; Moir et al., 2008; Wei
et al., 2011). Unlike in mice, B220 expression on human B cells
is dynamic, being lost during GC differentiation. As a likely con-
sequence, ∼60% of CD27+ memory-phenotype human B cells
are normally B220neg (Bleesing and Fleisher, 2003; Sanz et al.,
2008). Unlike the CD27+ compartment in healthy subjects, the
few remaining CD27+ B cells in patients with CD40L defects
tend to be B220+ (Bleesing and Fleisher, 2003). This observation
could indicate that the B220+CD27+ cells arise independently
of GC, and/or of T cell help delivered by CD40L. Curiously,
however, healthy-human CD27+ B cells expressing B220 have
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a greater propensity for CD21 loss and CD95 expression com-
pared with the CD27+B220neg cells (Morrow et al., 2008). It will
be informative to compare expression of these various mark-
ers in human conditions including post-vaccination, infection,
and immunodeficiency using advanced analysis techniques, as
described below.
The anti-idiotype component of our memory B cell panel,
rat anti-human monoclonal antibody clone 9G4, at once allows
Table 2 | Human memory B cell panel as per Wei et al. (2011).
Marker Purpose/function
Aqua live/dead dye Dead cell/debris exclusion
CD3 T cell exclusion
CD19 B lineage cell inclusion
IgD Non-switched BCR isotype
CD27 Memory/activation
CD38 Differentiation
CD24 Differentiation
CD21 BCR co-receptor down-regulated upon activation
CD95 FAS death receptor up-regulated upon activation
CXCR3 Inflamed tissue homing receptor
B220 (CD45 isoform) Differentiation/9G4+ Ab target autoantigen
9G4 BCR self-reactive idiotype
intrinsic detection of self-reactivity but also can complicate accu-
rate measurement of B cells with the target self-reactive BCR. The
9G4 reagent detects human VH4.34-encoded immunoglobulin
heavy-chain protein. Among the self-antigens detected by VH4.34
(9G4+) antibodies is human B220 (Cappione et al., 2004). Thus,
circulating VH4.34 serum antibody bound to any B220+ B cell
is detected by the rat anti-human reagent 9G4. This “painting”
effect can be circumvented by incubating the cells in protein-
containing media for 1 h at 37˚C prior to staining with the 9G4
reagent (Cappione et al., 2004; Kobie et al., 2012).
Despite the numerous advantages of high-parameter
fluorescence-based cytometry, developing and using 12- to 18-
color panels is a significant challenge due to complications such as
spectral overlap of the fluorescence signals, which becomes more
problematic with increasing numbers of dyes. To circumvent such
issues, DVD Sciences has developed Cytometry Time-of-Flight
(CyTOF) analysis as an alternative method (Maecker et al., 2012).
CyTOF mass cytometry detects cellular proteins bound by anti-
body (and other) reagents labeled with heavy isotopes of rare
earth metals, whereas rhodium- and iridium-conjugated DNA
intercalators are used for dead cell exclusion (Maecker et al.,
2012). Besides nearly eliminating the need for channel compensa-
tion, the sensitivity of signals among isotopes is less variable than
among fluorochromes (twofold versus 10- to 50-fold, respectively;
Maecker et al., 2012). Thus far, 30 parameters have been simultane-
ously analyzed using this approach (Bendall et al., 2011; Maecker
FIGURE 1 | Human B cell subsets identified with an established
memory B cell fluorescent reagent panel (see Wei et al., 2011).
Schematized flow cytometry plot (gated on viable PBMC CD19+ B cells)
indicates four core B cell subsets (gray ovals) defined by CD27 and IgD
expression. SwMe, switched memory; DN, double-negative; NSM,
non-switched memory. The naïve core subset can be further subdivided
into transitional and mature-naïve B cells. Distinguishing T3 from
mature-naïve requires a mitochondrial dye extrusion step not included in
the memory B cell panel. The switched memory and CD27+/int
memory-phenotype core subsets can be further evaluated for changes
(thick red and green arrows) in the indicated markers known to be
associated with B cell activation.
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et al., 2012). However, with CyTOF, there is a threefold lower sam-
pling efficiency and 25-fold lower flow rate (2 million cells/h)
as well as lower staining indices than with fluorescence cytom-
etry (Maecker et al., 2012). An additional limitation of CyTOF
is the inability to recover viable or even intact cells because the
mass cytometer needs to vaporize the cell for ionization (Maecker
et al., 2012). Despite these current limitations that are impracti-
cal for very large numbers of samples, mass cytometry will likely
develop into an advantageous tool allowing elaborate subsetting
to be coupled with the detection of multiple indicators of intra-
cellular signaling events such as protein phosphorylation (Bendall
et al., 2011).
PRIMARY CYTOMETRY ANALYSIS
We previously described fluorescence cytometry event-gating
strategies for our memory B cell panel using FlowJo software
(TreeStar, Inc.; Wei et al., 2011; Kaminski et al., 2012), which, just
as importantly as bench-level and instrumentation considerations,
needs to be standardized for large studies. Critical considerations
include the importance of: (1) excluding non-viable events and
debris with a viability-discriminating dye, (2) excluding cell dou-
blets and clumps using the various geometric dimensions of the
light-scatter channels (FSC and SSC height versus width), and (3)
choosing optimal scaling of plot axes to visualize and accurately
gate all events, (4) focusing on the morphological scatter proper-
ties of the target parent population (i.e., lymphocytes; Herzenberg
et al., 2006; Kaminski et al., 2012). In this latter regard, note that
plasma cells and activated B cells can be large and have some
granularity. Faithfully documenting gating strategies ensures con-
sistency and facilitates the ability of other researchers to reproduce
the results. An open-source R-package specification called Gating
Markup Language (Gating-ML) aims to simplify such documen-
tation and its exchange among users (Spidlen et al., 2008). In either
case, gating, including what may be considered “pre-gating” steps
to focus on the parental population (e.g., total B cells) should
always be reported in figure legends and/or methods sections of
publications. Citing published methods and OMIP-type articles
can allow this description to remain concise.
Conventional manual gating of flow cytometry data, as
described above, has served productively for many studies. How-
ever, this analysis approach has not kept pace with advances
in fluorescent reagent development and instrumentation. Spe-
cific criticisms and short-comings of conventional manual gat-
ing include: (1) gated regions drawn by users may be unnatural
and subjective boundaries that separate “populations” whose con-
stituents may share unappreciated commonalities, (2) the iterative
steps narrow how many events are available, and thus limit full uti-
lization of high-parameter panels, and (3) user-to-user variation
is inherent in such approaches. To begin addressing these issues,
automated analysis methods are under development. One such
approach is a density-based, model-independent algorithm called
Flow Clustering without k (FLOCK; Qian et al., 2010), which is
available through ImmPort (see text footnote 1) FLOCK identifies
event clusters (populations) in cytometer data files (fcs files) based
on simultaneous assessment of multiple fluorescent and scatter
parameters. In this approach, the high-dimensional space formed
by fluorescent parameter is partitioned with hyperbins, forming
hyper-regions of events. Event-dense hyper-regions are merged
with neighbors to form initial event clusters, followed by the cal-
culation of a centroid for each event cluster. Euclidean distance
between each event and the nearest centroid is used to assign the
remaining events that are not in the event-dense hyper-regions to
final clusters (populations). Using FLOCK, our group previously
identified 17 event clusters of B lineage cells in healthy-subject
PBMC stained with a 10-color fluorescent reagent panel (Qian
et al., 2010). In the same study, three populations of plasmablast
phenotype cells were identified whose post-vaccination kinetics
very closely followed the functional ASC response, as detected by
ELISpot assay.
Using our 12-color panel (Wei et al., 2011), we more recently
identified 25 B cell event clusters (populations, for simplicity;
Figure 2A; Table 3) that we arbitrarily categorized into seven
patterns according to IgD and CD27 expression based on conven-
tionally defined subsets (Figure 2B). Whereas five of these clusters
had a majority of their events in the IgD+CD27neg region of the
plot, six populations had a naïve-phenotype center plus several
events also in the CD27+ region (Figure 2B, Patterns 1 and 2,
respectively). Thus, based on simultaneous assessment of all fluo-
rescent parameters in the analysis, these latter CD27+ events have
more in common with their cluster-mates in the“naïve”area of the
plot than they do with the other events conventionally assigned
to the non-switched memory area of the plot. Putative biolog-
ical relevance (e.g., common differentiation pathways) of these
algorithm-defined associations remains to be validated. Notably,
only one of the populations (Pattern 5) contained a majority of
events in the non-switched memory area, accounting for 2.61%
of the CD19+ parent population. Thus, the remaining 8.3% of
the “non-switched memory” gate defined by conventional manual
gating (not shown) of this particular sample may be more related
to other subsets (e.g., those in the switched memory area, as in
Pattern 7 ) than they are to each other. This outcome supports the
concept that the IgD+CD27+ fraction may be a heterogeneous
mixture of B cell subsets, as discussed above. Importantly, several
established B cell subset characteristics were consistent in FLOCK
analysis compared with conventional gating, as described earlier.
This includes finding 9G4+ (likely autoreactive) B cells exclusively
in naïve-phenotype clusters, and CD95 expression only in CD27+
clusters in the non-autoimmune subject analyzed here (Figure 2C;
Table 3).
The results in Figure 2 raise important questions about the
potential B cell differentiation pathways from which our conven-
tionally defined core peripheral B cell subsets derive. Are there
some pathways in which CD27 is acquired before versus after
loss of IgD, and vice-versa, if IgD is lost at all? Thus, an unsuper-
vised FLOCK approach as demonstrated in Figure 2 can be used
for hypothesis generation and exploratory profiling. In parallel, a
supervised version of FLOCK is under development to incorpo-
rate user knowledge about cell populations and reagent panels to
allow for a closer recapitulation of manual gating, if desired. In this
way, researchers in a large study using the same reagent panel can
establish the FLOCK settings desired, and then perform numerous
cross-sample comparisons of hundreds of samples (in minutes per
sample), which would otherwise be extremely labor-intensive by
manual gating.
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FIGURE 2 | Event clusters identified by FLOCK analysis. FLOCK (Qian
et al., 2010) version 1.0 was run unsupervised on human PBMC stained
with the 12-color memory B cell reagent panel described in OMIP-003 (Wei
et al., 2011) pre-gated on single, viable CD19+ lymphoid events. (A) Overlay
of 25 populations, indicated in unique colors, identified in the sample
displayed as two-dimensional plots. (B) Representative event clusters of
the indicated Patterns based on CD27 versus IgD signals. Numbers below
the plots indicate IDs of populations (seeTable 3) with similar event
distributions as displayed in the corresponding plot. (C) Population 19
displayed as all parameters analyzed by FLOCK. In (B,C), white events on
the gray background are the total CD19+ population, for reference.
Characteristics of all 25 populations can be found inTable 3.
In addition to FLOCK, other event-analysis methods are under
development, varying in clustering methods, whether a pre-
determined number of clusters is used, modeling approaches,
scalability, degree of supervision, etc. (Naim et al., 2010; Aghaeep-
our et al., 2012; Chattopadhyay and Roederer, 2012; Maecker
et al., 2012). The SPADE (spanning-tree progression analysis of
density-normalized events) algorithm goes a step further by map-
ping how the event cluster populations phenotypically relate to
each other (Qiu et al., 2011). SPADE analysis produced a map
of mouse bone marrow populations that recapitulated known
hematopoietic differentiation stages of the cell phenotypes (Qiu
et al., 2011). Another analysis using the flowMeans event cluster-
ing algorithm identified human peripheral T cell subset phenotype
groups that were informative for predicting clinical progression to
AIDS based on an analysis pipeline called FlowType (Chattopad-
hyay and Roederer, 2012). Given the various programs’ complexity
and developmental status, determining which of the increasing
number of available analysis algorithms would be most effective
for a particular study may seem overwhelming to the immuno-
logical biologist. For this reason, the cytometry community, with
support from the NIH, has invested in a series of evaluations
called FlowCAP (Flow Cytometry: Critical Assessment of Popula-
tion Identification Methods2). In this approach, identical data sets
are evaluated by each algorithm in a series of Challenges to directly
compare the programs, identify areas for improvement, and dis-
cuss possible standards for the cytometry analysis field. These
efforts will facilitate the ability of the immunology research com-
munity to more fully take advantage of the numerous advances in
B cell phenotyping described above.
MANAGEMENT OF CYTOMETRY DATA AND ANALYTICAL
RESULTS
Regardless of the primary analysis method used, the enormous
amounts of data generated by large multiparameter flow cytome-
try studies need to be managed efficiently together with clinical
data for informative and non-redundant output. Housing and
structuring the data in a relational database can facilitate such
management. The Research Electronic Data Capture (REDCap)
database developed at Vanderbilt University is an example of a
comprehensive system for clinical data management (Harris et al.,
2009). Options for downstream biological laboratory data man-
agement include LabKey (labkey.com) as well as Cytobank, a web-
based resource modeled after gene expression data repositories in
which scientists can perform comprehensive storage, organization,
analysis, and sharing of flow cytometry data files (Kotecha et al.,
2010). Once the data are further analyzed (described below) and
ready for publication, their contributions in advancing scientific
knowledge are best utilized if standards of adequate documen-
tation are adhered to. MIFlowCyt (Minimum Information about
a Flow Cytometry experiment) is a recommended standard for
metadata to promote effective data set description for publication
and to enhance reproducibility of analytical results. MIFlowCyt
components are experiment overview, details about the specimen,
data analysis details, and instrument details (Lee et al., 2008).
Finally, B cell phenotyping data need to be comprehensively
analyzed to enable meaningful conclusions to be drawn from large
human studies. Conventional graphing techniques are easily over-
whelmed by the numbers of cell populations, the numbers of sub-
jects and their treatments, and corresponding clinical read-outs
involved in such studies. This issue can be addressed with more
global profiling approaches in which all data are considered simul-
taneously, revealing system-wide views of immune-cell popula-
tions. Data clustering displayed in heat maps (color-coded sample-
by-feature matrices, as are extensively used for gene expression
2flowcap.flowsite.org
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Table 3 | Characteristics of PBMC B cell clusters identified by FLOCK.
Popln IgD CD27 CD38 CD24 CD21 CD95 CXCR3 B220 9G4 % of CD19+
Pattern 1 3 + − + + + − − + − 12.80
9 + − Low Low + − − + − 11.06
11 + − + + + − − + − 6.41
21 + − Low/− +/Low +/Low − − + − 5.51
25 + − + Low/− − − − + + 2.04
Pattern 2 16 + −/+ Low/− + +/Low − − + − 2.99
19 + −/+ High/+ +/Low + − − + + 5.12
20 + −/+ +/Low +/Low + − − + − 7.29
22 + −/+ + + +/Low − ± + + 2.95
23 + −/+ − − − − − + − 3.17
24 + −/+ Low/− Low/− − − − +/Low − 5.00
Pattern 3 2 Low − Low Low + − − + − 5.64
7 Low − + + + − − − − 1.47
12 Low − High High Low/− − − + − 2.13
Pattern 4 1 − −/+ Spread − − − − ± − 1.34
Pattern 5 17 + + Low/− + + − − +/Low − 2.61
Pattern 6 4 − + Low/− Low/− ± + − Low/− − 1.56
Pattern 7 5 −/+ + − + + − − +/Low − 2.74
6 −/+ + Low/− + + − − +/Low − 4.14
8 −/+ + − + + − − + − 2.31
10 −/+ + ± + +/Low − ± − − 1.49
13 −/+ + ± + + − − − − 2.61
14 −/+ + +/Low + + − + +/Low − 2.05
15 −/+ + +/Low + + − − Low − 2.94
18 −/+ + ± ± ± ± + +/Low − 2.63
FLOCK analysis of B cells was performed as described (Qian et al., 2010) with samples of non-autoimmune PBMC stained with the OMIP-003 memory B cell panel
(Wei et al., 2011). Event cluster (popln) ID numbers and Pattern numbers correspond with Figure 2. Indicated are the marker expression levels for the cluster’s center.
The identical phenotypes of populations 3 and 11 may result from overpartitioning by FLOCK.
Note that the autoreactive idiotype 9G4 populations add-up to 10.1% and are found exclusively in naïve-phenotype (IgD+CD27neg) clusters, consistent with previous
observations by manual gating of non-autoimmune subjects.
analysis) offers many options for addressing experimental ques-
tions with a particular data set (D’Haeseleer, 2005). Hierarchical
clustering seeks natural groupings of samples by partitioning data
to minimize the distances (Euclidean distance, Pearson correla-
tion, or Spearman correlation) among the samples within each
group compared to distances among samples from different clus-
ters (D’Haeseleer, 2005; Habib and Finn, 2006; Diaz-Romero et al.,
2010; Blekherman et al., 2011). For example, hierarchical cluster-
ing with complete linkage and Pearson’s correlation as the distance
metric identified 3–4 clusters of B-CLL patients based on the flow
cytometry-defined characteristics of their circulating tumor cells
(Habib and Finn, 2006). Further analysis of this data showed that
patients in a cluster characterized by CD38low B lineage tumor
cells correlated with longer patient survival (Habib and Finn,
2006). Similarly, clustering organizes the populations so that those
that vary in a similar fashion over the set of samples are grouped
together. In SLE, k-means clustering, an alternative approach with
a pre-specified number of clusters, based on Euclidean distance
among clinical and demographic features, identified three patient
groups, one of which correlated with a high mortality rate (To et al.,
2009). It will be advantageous to combine these types of infor-
mative analyses with the above-described advances in extensive
phenotypic B cell subsetting to identify clinical-associated sig-
natures in multiple areas, including infection and autoimmunity
prognosis, vaccine responses, and transplant tolerance.
Displaying clustered data as heat maps may suffice for address-
ing the experimental question of a particular study. However,
in some cases, a related and complementary data exploration
approach, Principal Component Analysis (PCA) can elucidate how
the variation of analyzed cell populations (variables) informs us
about clinically useful relationships among the data. PCA is a
dimension-reduction technique that expresses the original data
as a set of new, transformed variables that are linear combinations
of the original variables. Because many of the original variables are
likely to be correlated across a set of samples, a large fraction of the
total variance in the data set is captured in the first few so-called
principal components (Quackenbush, 2001; Misra et al., 2002). In
this way, the high dimensionality of the data is reduced into a form
that is more easily visualized and comprehended (Blekherman
et al., 2011). Note that PCA is unsupervised in that no information
about sample group membership is supplied and that most of the
variation in a data set, captured by the first two principal compo-
nents may be due to process variability or noise, and not the result
of a biological or clinical cause. Nonetheless, by superimposing
Frontiers in Immunology | B Cell Biology October 2012 | Volume 3 | Article 302 | 10
Kaminski et al. Human B cell phenotyping
sample group membership onto samples in a PCA plot, segre-
gation of groups can be revealed. For example, PCA (as well as
data clustering) on flow cytometry-derived data has shown T cell
subsets that are higher in centenarians compared with younger
individuals (Lugli et al., 2007).
CONCLUDING REMARKS
The phenotypic diversity of human B cell subsets provides an
opportunity to interrogate B profiling to revolutionize immuno-
logical disease diagnosis and optimize treatment modalities,
including, but not limited to, B cell-targeted therapies. Coupling
cytometry-based phenotypic B cell analysis with cell morphology,
immunoglobulin gene analysis (V region usage and somatic hyper-
mutation patterns), functional in vitro assays (including cytokine
and antibody secretion), and profiling after B cell-targeted ther-
apies can also further elucidate the mechanisms driving such
diseases, paving the way for more optimized therapies, as well
as understanding normal B cell biology, which can be harnessed
for improved vaccine development. Importantly, the limitations
once thought to restrict human immunology to pauci-informative
descriptive analysis can be overcome with improvements in flow
cytometry per se, as well as developing advances in flow data
analysis and data management infrastructure.
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